What's on your mind?

There's both much to know and much to say and we'd like to hear from you; your ideas, your experiences... anything that helps provide perspective on lives that have been impacted by diseases of the central nervous system.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
May 16, 2023

Cerevance Announces Oral Presentation of Phase 1 Data on CVN766 at American Society of Clinical Psychopharmacology (ASCP)

Cerevance today announced plans to present an oral presentation at the upcomingAmerican Society of Clinical Psychopharmacology (ASCP) conference, taking place in Miami, Florida, May 30 – June 2, 2023.

Read Full

Breakthrough Science for the Central Nervous System

Diseases of the Central Nervous System aren't just a problem, they're personal. Our revolutionary discovery of solutions for diseases centered in the brain continues where they begin; where science meets people.  

The Story

Precise. Unique. Life Changing.

NETSseq Platform: Identifying targets for safer, more effective therapeutics

Discovering and Validating Novel Targets Using the Most Comprehensive Brain Tissue Data Base

With the vast genomic content murmurating in the human brain, we take notice when our NETSseq platform points out differences.

Advanced Pipeline

PIPELINE HIGHLIGHT:  Novel therapies with cell-type specific targeted approach

Proprietary NETSseq platform more precisely targets disease mechanisms and is validated with Phase 3-ready CVN424

DISCOVERY
LEAD OPTIMIZATION
PHASE II
PHASE III
PHASE I
IND ENABLING
CVN424
Parkinson's disease
CVN766
Psychiatric disorders (negative and cognitive symptoms of schizophrenia)
CVN293
Neuroinflammation in ALS and Alzheimer’s disease
CVN398
Disease modification in Parkinson’s Disease
Target-18
Parkinsons disease
Multiple early targets
Adjunctive Therapy
Monotherapy

Cerevance: It's Personal

A FOUNDER'S JOURNEY

It reads like an Icelandic saga. A family; father, mother, children...and their quest for the cure for maladies of the brain and central nervous system (CNS). Fast forward 20 years –

Cerevance is the result; a gathering of rare minds creating solutions to what was the black box of the brain and central nervous system. Recent clinical data reveals remarkable advantages in patient outcomes. The prospects for real people, families and communities living with those afflicted with the most life changing CNS diseases have never been more hopeful.

LIghtstone Ventures
Takeda
Google Venture
Dimentia Discovery Fund
UPMC Enterprises
Foresite Capital
Casdin Capital
Dolby Family Ventures
Bill Gates